Off-label drugs for weight management

References

• Maffetone PB Rivera-Dominguez I Laursen PB Overfat and underfat: new terms and definitions long overdue Front Public Health 2016 4 279 28097119
   PubMed Web of Science ®Google Scholar
• Halford JC Boyland EJ Blundell JE Kirkham TC Harrold JA Pharmacological management of appetite expression in obesity Nat Rev Endocrinol 2010 6 5 255 269 20234354
   PubMed Web of Science ®Google Scholar
• Greenway FL Fujioka K Plodkowski RA Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2010 376 9741 595 605 20673995
   PubMed Web of Science ®Google Scholar
• Rebello CJ Greenway FL Reward-induced eating: therapeutic approaches to addressing food cravings Adv Ther 2016 33 11 1853 1866 27718159
   PubMed Web of Science ®Google Scholar
• Thomas EA Mcnair B Bechtell JL Ferland A Cornier MA Eckel RH Greater hunger and less restraint predict weight loss success with phentermine treatment Obesity (Silver Spring) 2016 24 1 37 43 26584649
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Greenway FL Westman EC Gupta AK Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity Obesity (Silver Spring) 2011 19 12 2351 2360 21527891
   PubMed Web of Science ®Google Scholar
• CenterWatch. [database on the Internet] FDA Approved Drugs by Therapeutic Area Available from: http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology Accessed May 23, 2017
   Google Scholar
• Thomas CE Mauer EA Shukla AP Rathi S Aronne LJ Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s Obesity (Silver Spring) 2016 24 9 1955 1961 27569120
   PubMed Web of Science ®Google Scholar
• Bhat SP Sharma A Current drug targets in obesity pharmacotherapy – a review Curr Drug Targets Epub 2017 2 27
   Web of Science ®Google Scholar
• Okorodudu DO Jumean MF Montori VM Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis Int J Obes 2010 34 5 791 799
   PubMed Web of Science ®Google Scholar
• Shah NR Braverman ER Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin PLoS One 2012 7 4 e33308 22485140
   PubMed Web of Science ®Google Scholar
• Blundell JE Dulloo AG Salvador J Frühbeck G EASO SAB Working Group on BMI Beyond BMI – phenotyping the obesities Obesity Facts 2014 7 5 322 328 25485991
   PubMed Web of Science ®Google Scholar
• Boulenouar S Michelet X Duquette D Adipose type one innate lymphoid cells regulate macrophage homeostasis through targeted cytotoxicity Immunity 2017 46 2 273 286 28228283
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Rothman RB Greenway FL How physician obesity specialists use drugs to treat obesity Obesity (Silver Spring) 2009 17 9 1730 1735 19300434
   PubMed Web of Science ®Google Scholar
• Schmidt SL Bryman D Greenway FL Hendricks EJ How physician obesity medicine specialists treated obesity before 2012 new drug approvals Obes Surg 2015 25 1 186 190 25344465
   PubMed Web of Science ®Google Scholar
• Colman E Anorectics on trial: a half century of federal regulation of prescription appetite suppressants Ann Intern Med 2005 143 5 380 385 16144896
   PubMed Web of Science ®Google Scholar
• Frank A The long-term management of obesity with continuing pharmacotherapy Obes Res 2004 12 11 1821 1827 15601978
   PubMedGoogle Scholar
• Apovian CM Aronne LJ Bessesen DH Pharmacological management of obesity: an endocrine Society clinical practice guideline J Clin Endocrinol Metab 2015 100 2 342 362 25590212
   PubMed Web of Science ®Google Scholar
• Miguelgorry PL Hendricks EJ Pharmacotherapy for obesity and changes in eating behavior: a patient and physician’s perspective Adv Ther 2016 33 7 1262 1266 27246171
   PubMed Web of Science ®Google Scholar
• Douglas A Douglas JG Robertson CE Munro JF Plasma phentermine levels, weight loss and side-effects Int J Obes 1983 7 6 591 595 6654575
   PubMed Web of Science ®Google Scholar
• Haddock CK Poston WS Foreyt JP DiBartolomeo JJ Warner PO Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation Eat Weight Disord 2008 13 2 95 101 18612258
   PubMed Web of Science ®Google Scholar
• Rothman RB Treatment of obesity with combination pharmacotherapy Am J Ther 2010 17 6 596 603 19352140
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Srisurapanont M Schmidt SL Addiction potential of phentermine prescribed during long-term treatment of obesity Int J Obes (Lond) 2014 38 2 292 298 23736363
   PubMed Web of Science ®Google Scholar
• Stevens JR Wilens TE Stern TA Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges Prim Care Companion CNS Disord 2013 15 2
   Google Scholar
• Alexander M Rothman RB Baumann MH Endres CJ Brasic JR Wong DF Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis Synapse 2005 56 2 94 99 15729739
   PubMed Web of Science ®Google Scholar
• Pagoto SL Curtin C Lemon SC Association between adult attention deficit/hyperactivity disorder and obesity in the US population Obesity (Silver Spring) 2009 17 3 539 544 19131944
   PubMed Web of Science ®Google Scholar
• Lorber J Obesity in childhood. A controlled trial of anorectic drugs Arch Dis Child 1966 41 217 309 312 5328625
   PubMed Web of Science ®Google Scholar
• Caterson ID Finer N Coutinho W Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial Diabetes Obes Metab 2012 14 6 523 530 22192338
   PubMed Web of Science ®Google Scholar
• de las Fuentes L Waggoner AD Mohammed BS Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function J Am Coll Cardiol 2009 54 25 2376 2381 20082927
   PubMed Web of Science ®Google Scholar
• Bryman D Hendricks EJ Schmidt SL Incidence of addiction and abuse due to phentermine, diethylpropion, and phendimetrazine in the United States Telephone Survey of Emergency Rooms and Addiction Treatment Centers ed. Unpublished manuscript 2013
   Google Scholar
• American Psychiatric Association, DSM-5 Task Force Diagnostic and Statistical Manual of Mental Disorders: DSM-5 5th ed American Psychiatric Association Arlington, VA 2013
   Google Scholar
• Hendricks EJ Rothman RB RE: pulmonary hypertension associated with use of phentermine? Yonsei Med J 2011 52 5 869 870 21786457
   PubMed Web of Science ®Google Scholar
• Rothman RB Baumann MH Savage JE Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications Circulation 2000 102 23 2836 2841 11104741
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Greenway FL A study of abrupt phentermine cessation in patients in a weight management program Am J Ther 2011 18 4 292 299 20592662
   PubMed Web of Science ®Google Scholar
• Berridge KC Robinson TE Liking, wanting, and the incentive-sensitization theory of addiction Am Psychol 2016 71 8 670 679 27977239
   PubMed Web of Science ®Google Scholar
• Schoedel KA Addy C Chakraborty B Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users J Clin Psychopharmacol 2012 32 4 492 502 22722508
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Rothman RB Phentermine therapy for obesity does not elevate blood pressure Diabetes Obes Metab 2011 13 10 963 964 21896124
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study Diabetes Care 2012 35 4 731 737 22442396
   PubMed Web of Science ®Google Scholar
• Seifarth C Schehler B Schneider HJ Effectiveness of metformin on weight loss in non-diabetic individuals with obesity Exp Clin Endocrinol Diabetes 2013 121 1 27 31 23147210
   PubMed Web of Science ®Google Scholar
• Igel LI Sinha A Saunders KH Apovian CM Vojta D Aronne LJ Metformin: an old therapy that deserves a new indication for the treatment of obesity Curr Atheroscler Rep 2016 18 4 16 26888066
   PubMed Web of Science ®Google Scholar
• Shorvon SD Safety of topiramate: adverse events and relationships to dosing Epilepsia 1996 37 Suppl 2 S18 S22 8641242
   PubMed Web of Science ®Google Scholar
• Shapira NA Goldsmith TD McElroy SL Treatment of binge-eating disorder with topiramate: a clinical case series J Clin Psychiatry 2000 61 5 368 372 10847312
   PubMed Web of Science ®Google Scholar
• Bray GA Hollander P Klein S A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 2003 11 6 722 733 12805393
   PubMedGoogle Scholar
• Smith SR Garvey WT Greenway FL Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study Obesity (Silver Spring) 2017 25 5 857 865 28440045
   PubMed Web of Science ®Google Scholar
• Hollander P Bays HE Rosenstock J Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial Diabetes Care 2017 40 5 632 639 28289041
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C Nguyen H Schauerhamer MB Glycemic control and weight outcomes for exenatide once weekly versus liraglutide in patients with type 2 diabetes: a 1-year retrospective cohort analysis Clin Ther 2016 38 12 2642 2651 27889301
   PubMed Web of Science ®Google Scholar
• Gadde KM Kopping MF Wagner HR2nd Yonish GM Allison DB Bray GA Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial Arch Intern Med 2012 172 20 1557 1564 23147455
   PubMedGoogle Scholar
• Gadde KM Yonish GM Foust MS Wagner HR Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study J Clin Psychiatry 2007 68 8 1226 1229 17854247
   PubMed Web of Science ®Google Scholar
• Aronne L Fujioka K Aroda V Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a Phase 2, randomized, placebo-controlled, dose-escalation study J Clin Endocrinol Metab 2007 92 8 2977 2983 17504894
   PubMed Web of Science ®Google Scholar
• Sumithran P Prendergast LA Delbridge E Long-term persistence of hormonal adaptations to weight loss N Engl J Med 2011 365 17 1597 1604 22029981
   PubMed Web of Science ®Google Scholar
• Rosenbaum M Leibel RL Brain reorganization following weight loss Nestle Nutr Inst Workshop Ser 2012 73 1 20 23128762
   PubMedGoogle Scholar
• Whigham LD Dhurandhar NV Rahko PS Atkinson RL Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status Int J Obes (Lond) 2007 31 5 850 857 17146452
   PubMed Web of Science ®Google Scholar
• Yu E Ley SH Manson JE Weight history and all-cause and cause-specific mortality in three prospective cohort studies Ann Intern Med 2017 166 9 613 620 28384755
   PubMed Web of Science ®Google Scholar
• Lin L Peng K Du R Metabolically healthy obesity and incident chronic kidney disease: The role of systemic inflammation in a prospective study Obesity (Silver Spring) 2017 25 3 634 641 28160438
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez D Sanchez-Inigo L Fernandez-Montero A Pastrana-Delgado J Alfredo Martinez J Are all metabolically healthy individuals with obesity at the same risk of diabetes onset? Obesity (Silver Spring) 2016 24 12 2615 2623 27804254
   PubMed Web of Science ®Google Scholar
• Chang Y Ryu S Choi Y Metabolically healthy obesity and development of chronic kidney disease: a cohort study Ann Intern Med 2016 164 5 305 312 26857595
   PubMed Web of Science ®Google Scholar
• Montesi L El Ghoch M Brodosi L Calugi S Marchesini G Dalle Grave R Long-term weight loss maintenance for obesity: a multidisciplinary approach Diabetes Metab Syndr Obes 2016 9 37 46 27013897
   PubMed Web of Science ®Google Scholar
• Wadden TA Berkowitz RI Womble LG Randomized trial of lifestyle modification and pharmacotherapy for obesity N Engl J Med 2005 353 20 2111 2120 16291981
   PubMed Web of Science ®Google Scholar
• FDA Guidance for the Clinical Evaluation of Weight-Control Drugs CDER Washington, DC Food and Drug Administration 1996
   Google Scholar